文章：

社区肿瘤学实践中Cemiplimab治疗晚期皮肤鳞状细胞癌的疗效与毒性评估

Effectiveness and Toxicity of Cemiplimab Therapy for Advanced Cutaneous Squamous Cell Skin Cancer in a Community Oncology Practice

原文发布日期：27 February 2025

DOI: 10.3390/cancers17050823

类型: Article

开放获取: 是

英文摘要：

Background: The immune checkpoint inhibitor cemiplimab has significant clinical activity in unresectable and metastatic cutaneous squamous cell carcinomas. There are limited real-world data available to assess the outcome of cemiplimab treatment in patients in a community practice setting. Methods: We conducted a retrospective analysis of treatment outcomes following cemiplimab treatment (350 mg IV every 3 weeks) of squamous cell skin cancer. An exploratory analysis was performed to evaluate patient subsets, including patients with locally advanced disease, regional or distant metastases, and “too numerous to count” primaries. Another small group of patients who did not respond to the initial four doses of cemiplimab were evaluated following added radiotherapy. Results: Of the 36 patients treated, 22 (61.1%) achieved complete remission, 10 (27.8%) experienced a partial response, 3 (8.3%) had stable disease, and 1 (2.8%) developed progressive disease. The median progression-free survival for the entire cohort was over 33 months. Overall, cemiplimab was well-tolerated, with no hospitalizations due to treatment-related toxicity. Conclusions: Cemiplimab produced complete remissions in over 60% of patients with locally advanced and metastatic squamous cell skin cancers, allowing elective treatment discontinuation. Addition of radiotherapy in cemiplimab-refractory patients appeared to increase tumor responsiveness. In contrast, patients with TNTC primary tumors frequently develop new primary skin cancers. Thus, improved treatment options for this patient subset are still needed.

摘要翻译： 

背景：免疫检查点抑制剂西米普利单抗在不可切除和转移性皮肤鳞状细胞癌中展现出显著的临床活性。目前评估该药物在社区实践环境中治疗结局的真实世界数据有限。方法：我们对接受西米普利单抗（每3周静脉注射350 mg）治疗的皮肤鳞状细胞癌患者进行回顾性疗效分析。通过探索性分析评估不同患者亚组，包括局部晚期疾病、区域或远处转移以及原发灶"多不可数"的患者。另对初始四剂西米普利单抗治疗无应答的小规模患者群体，评估联合放疗后的治疗效果。结果：在36例接受治疗的患者中，22例（61.1%）达到完全缓解，10例（27.8%）实现部分缓解，3例（8.3%）疾病稳定，1例（2.8%）出现疾病进展。全队列中位无进展生存期超过33个月。总体而言，西米普利单抗耐受性良好，未出现因治疗相关毒性导致的住院事件。结论：西米普利单抗使超过60%的局部晚期和转移性皮肤鳞状细胞癌患者获得完全缓解，为选择性终止治疗提供了可能。对西米普利单抗耐药患者联合放疗可增强肿瘤应答。相比之下，原发灶"多不可数"患者常出现新发原发性皮肤癌，该亚组患者仍需改进治疗方案。

原文链接：

Effectiveness and Toxicity of Cemiplimab Therapy for Advanced Cutaneous Squamous Cell Skin Cancer in a Community Oncology Practice